Evaluation of in vitro in vivo correlations for dry powder inhaler delivery using artificial neural networks.

The aim of these experiments was to investigate the use of artificial neural networks (ANNs) for generating models able to predict the relative lung bioavailability and clinical effect of salbutamol when delivered to healthy volunteers and asthmatic patients from dry powder inhalers (DPIs). ANN software was used to model in vitro, demographic and in vivo data from human subjects for four different DPI formulations containing salbutamol sulfate. In 12 volunteers, a model linking the in vitro aerodynamic characteristics of the emitted dose and volunteer body surface area with the urinary excretion of drug and its metabolite in the 24h period after inhalation was established. In 11 mild asthmatics, a predictive model correlating in vitro data, baseline lung function, body surface area and age with post-treatment improvements in forced expiratory volume in 1s (FEV1) was also generated. Models validated using unseen data from individual subjects receiving the different DPI formulations were shown to give predictions of in vivo performance. The squared correlation coefficients (R2) for plots comparing predicted and observed in vivo outcomes were 0.83 and 0.84 for urinary excretion and lung function data, respectively. It can therefore be concluded that ANN models have the potential to predict the in vivo performance of DPIs in individual subjects.

[1]  K. Brown,et al.  In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. , 2000, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[2]  H. Chrystyn,et al.  Determination of the relative bioavailability of salbutamol to the lung following inhalation. , 1992, British journal of clinical pharmacology.

[3]  B. Lipworth,et al.  Effects of airway calibre on lung delivery of nebulised salbutamol. , 1997, Thorax.

[4]  O. Usmani,et al.  Regional Lung Deposition and Bronchodilator Response as a Function of β2-Agonist Particle Size , 2005 .

[5]  Varsha Chavan,et al.  Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler , 2008, AAPS PharmSci.

[6]  W. Finlay,et al.  The effect of breathing pattern on nebulizer drug delivery. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[7]  J Bourquin,et al.  Application of artificial neural networks (ANN) in the development of solid dosage forms. , 1997, Pharmaceutical development and technology.

[8]  M. Svartengren,et al.  Deposition of large particles in human lung. , 1987, Experimental lung research.

[9]  D. Barlow,et al.  Artificial Neural Network Prediction of Aerosol Deposition in Human Lungs , 2002, Pharmaceutical Research.

[10]  Raymond C. Rowe,et al.  Intelligent Software for Product Formulation , 1998 .

[11]  Marcel de Matas,et al.  Evaluation of an in vitro in vivo correlation for nebulizer delivery using artificial neural networks. , 2007, Journal of pharmaceutical sciences.

[12]  M. Vahteristo,et al.  Comparison of two budesonide dry powder inhalers in the treatment of asthma in children. , 2004, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[13]  K. Amighi,et al.  Formulation and Characterization of Lipid-Coated Tobramycin Particles for Dry Powder Inhalation , 2006, Pharmaceutical Research.

[14]  K. Saunders,et al.  Influence of age on response to ipratropium and salbutamol in asthma. , 1981, Thorax.

[15]  R. Suedee,et al.  The study of in vitro-in vivo correlation: pharmacokinetics and pharmacodynamics of albuterol dry powder inhalers. , 2005, Journal of pharmaceutical sciences.

[16]  Peter York,et al.  Comparison of neurofuzzy logic and neural networks in modelling experimental data of an immediate release tablet formulation. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  J N Pritchard,et al.  The influence of lung deposition on clinical response. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[18]  D. Barlow,et al.  Artificial neural network prediction of the patterns of deposition of polydisperse aerosols within human lungs. , 2005, Journal of pharmaceutical sciences.

[19]  H. Bisgaard,et al.  Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer. , 1997, The European respiratory journal.

[20]  T. Niu,et al.  Familial aggregation of bronchodilator response: a community-based study. , 2000, American journal of respiratory and critical care medicine.

[21]  J A Dowell,et al.  Artificial neural networks applied to the in vitro-in vivo correlation of an extended-release formulation: initial trials and experience. , 1999, Journal of pharmaceutical sciences.

[22]  H. Chrystyn,et al.  Determination of the Relative Bioavailability of Salbutamol to the Lungs Following Inhalation from Dry Powder Inhaler Formulations Containing Drug Substance Manufactured by Supercritical Fluids and Micronization , 2007, Pharmaceutical Research.

[23]  H. Chrystyn,et al.  An investigation of in vitro/in vivo correlations for salbutamol nebulized by eight systems. , 2002, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[24]  J. Lammers,et al.  Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. , 1996, Thorax.

[25]  B O Stuart,et al.  Deposition of inhaled aerosols. , 1973, Archives of internal medicine.

[26]  C. Leach,et al.  Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[27]  Jaber Emami,et al.  In vitro - in vivo correlation: from theory to applications. , 2006, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[28]  H. Chrystyn,et al.  Standards for Bioequivalence of Inhaled Products , 1994, Clinical pharmacokinetics.

[29]  R. Hermann,et al.  Scintigraphic comparison of budesonide deposition from two dry powder inhalers. , 2000, The European respiratory journal.

[30]  Y. Cheng,et al.  Particle characteristics and lung deposition patterns in a human airway replica of a dry powder formulation of polylactic acid produced using supercritical fluid technology. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.